Cabotegravir (Apretude, ViiV Healthcare) is indicated 'in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg'.
The dosage schedule is available in the summary of product characteristics for cabotegravir.
The list price of cabotegravir is £1,197.02 for 1 vial of prolonged-release suspension for bimonthly injection and £638.57 for a 30-day pack of oral tablets (excluding VAT, BNF online accessed September 2025).
The company has a commercial arrangement. This makes cabotegravir available to the NHS with a discount via the Medicines Procurement and Supply Chain framework. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on ViiV Healthcare's website.